Ep. 364 - UCB’s Candid buy, Grand Rounds and leukodystrophies

Biopharma industry developments center on the $2 billion acquisition of Candid Therapeutics by UCB, signaling a strategic shift toward T cell engagers for autoimmune applications. This move underscores the necessity of clinical proof-of-concept in a crowded landscape. Leukodystrophy research is simultaneously evolving, with over two dozen biotechs moving beyond traditional enzyme replacement therapies toward RNA knockdown and brain-shuttle modalities to address white matter diseases. Meanwhile, the biotech IPO market exhibits renewed vitality, as evidenced by successful listings from Hemab, Seaport, and Avalin Pharma, driven by investor preference for validated, mechanism-based platforms. These trends, alongside advancements in protein design and transformer architectures, define the current R&D environment. The upcoming BioCentury Grand Rounds in Seattle will further explore these translational science bottlenecks and the integration of AI into drug discovery.